Revolution Medicines, Inc. Common Stock (RVMD) Financial Statements
Historical financial data — 22 statements covering FY2020–FY2022
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabiliti...
Revolution Medicines, Inc. Common Stock's revenue increased 20.4% year over year, from $29.4M to $35.4M.
Net income decreased 32.9% over the same period, from $-187.1M to $-248.7M.
Operating cash flow declined 52.5% to $-224.4M.
Revolution Medicines, Inc. Common Stock maintains a negative net profit margin of -703.0%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2021 | $1.1M-87.3% | $-52.9M | N/A | $-53.2M | $-36.6M | $735.0M | N/A | $638.2M |
| Q4 FY2021 | $9.5M+759.2% | $-52.7M | N/A | $-52.9M | $-39.3M | $738.0M | N/A | $602.6M |
| Q1 FY2022 | $7.6M-19.9% | $-57.6M | N/A | $-57.9M | $-55.2M | $682.8M | N/A | $551.0M |
| Q2 FY2022 | $9.1M+20.3% | $-61.2M | N/A | $-62.1M | $-55.7M | $632.8M | N/A | $498.8M |
| Q3 FY2022 | $3.4M-63.2% | $-73.3M | N/A | $-76.5M | $-51.7M | $825.9M | N/A | $681.4M |
| Q4 FY2022 | $15.3M+356.8% | $-56.5M | N/A | $-61.7M | $-61.8M | $811.9M | N/A | $685.2M |
| Q1 FY2023 | $7.0M-54.2% | $-68.1M | N/A | $-75.2M | $-62.4M | $1.07B | N/A | $952.2M |
| Q3 FY2023 | $3.8M-45.5% | $-206.7M | N/A | $-232.0M | $-167.6M | $984.2M | N/A | $837.5M |
Balance Sheet Summary (Latest Period)
Revolution Medicines, Inc. Common Stock (RVMD) Financial Statements & Revenue History
Revolution Medicines, Inc. Common Stock (RVMD) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry trading at $207.01 with a market capitalization of $44. This page provides 22 historical financial statements for Revolution Medicines, Inc. Common Stock, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Revolution Medicines, Inc. Common Stock reported revenue of $35 million, representing 20.4% year-over-year growth. The net profit margin of -703.0% indicates the company is currently unprofitable..
RVMD Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Revolution Medicines, Inc. Common Stock's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether RVMD is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track RVMD's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Revolution Medicines, Inc. Common Stock converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of RVMD's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use RVMD Financial Data
Investors use Revolution Medicines, Inc. Common Stock's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare RVMD's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how RVMD's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View RVMD's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Revolution Medicines, Inc. Common Stock's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.RVMD trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.